Department of Obstetrics and Gynecology, Hokkaido University School of Medicine, Sapporo, Japan.
Int J Cancer. 2013 Jan 15;132(2):327-34. doi: 10.1002/ijc.27680. Epub 2012 Jul 3.
We examined incidence probabilities of cervical intraepithelial neoplasia 3 (CIN3) or more severe lesions (CIN3+) in 1,467 adult Japanese women with abnormal cytology in relation to seven common human papillomavirus (HPV) infections (16/18/31/33/35/52/58) between April 2000 and March 2008. Sixty-seven patients with multiple HPV infection were excluded from the risk factor analysis. Incidence of CIN3+ in 1,400 patients including 68 with ASCUS, 969 with low grade squamous intraepithelial lesion (LSIL), 132 with HSIL without histology-proven CIN2 (HSIL/CIN2(-)) and 231 with HSIL with histology-proven CIN2 (HSIL/CIN2(+)) was investigated. In both high grade squamous intraepithelial lesion (HSIL)/CIN2(-) and HSIL/CIN2(+), HPV16/18/33 was associated with a significantly earlier and higher incidence of CIN3+ than HPV31/35/52/58 (p = 0.049 and p = 0.0060, respectively). This association was also observed in LSIL (p = 0.0002). The 1-year cumulative incidence rate (CIR) of CIN3+ in HSIL/CIN2(-) and HSIL/CIN2(+) according to HPV genotypes (16/18/33 vs. 31/35/52/58) were 27.1% vs. 7.5% and 46.6% vs. 19.2%, respectively. In contrast, progression of HSIL/CIN2(+) to CIN3+ was infrequent when HPV DNA was undetected: 0% of 1-year CIR and 8.1% of 5-year CIR. All cervical cancer occurred in HSIL cases of seven high-risk HPVs (11/198) but not in cases of other HPV or undetectable/negative-HPV (0/165) (p = 0.0013). In conclusion, incidence of CIN3+ depends on HPV genotypes, severity of cytological abnormalities and histology of CIN2. HSIL/CIN2(+) associated with HPV16/18/33 may justify early therapeutic intervention, while HSIL/CIN2(-) harboring these HPV genotypes needs close observation to detect incidence of CIN3+. A therapeutic intervention is not indicated for CIN2 without HPV DNA.
我们研究了 2000 年 4 月至 2008 年 3 月期间 1467 名细胞学异常的日本成年女性中 7 种常见的人乳头瘤病毒(HPV)感染(16/18/31/33/35/52/58)与宫颈上皮内瘤变 3 级(CIN3)或更严重病变(CIN3+)的发病概率之间的关系。对 67 例多重 HPV 感染患者进行了排除。在包括 68 例 ASCUS、969 例低度鳞状上皮内病变(LSIL)、132 例未行组织学证实的 CIN2 的高度鳞状上皮内病变(HSIL/CIN2(-))和 231 例有组织学证实的 CIN2 的 HSIL(HSIL/CIN2(+))患者中,对 CIN3+的发病率进行了研究。在 HSIL/CIN2(-)和 HSIL/CIN2(+)中,HPV16/18/33 与 CIN3+的发生时间更早、发病率更高显著相关,而 HPV31/35/52/58 则不然(p = 0.049 和 p = 0.0060)。这种关联在 LSIL 中也观察到(p = 0.0002)。根据 HPV 基因型(16/18/33 与 31/35/52/58),HSIL/CIN2(-)和 HSIL/CIN2(+)中 1 年 CIN3+累积发病率(CIR)分别为 27.1% vs. 7.5%和 46.6% vs. 19.2%。相比之下,当 HPV DNA 检测不到时,HSIL/CIN2(+)进展为 CIN3+的情况并不常见:1 年 CIR 为 0%,5 年 CIR 为 8.1%。所有宫颈癌均发生在 7 种高危 HPV(11/198)的 HSIL 病例中,但未发生在其他 HPV 或未检测到/阴性 HPV(0/165)的病例中(p = 0.0013)。综上所述,CIN3+的发病概率取决于 HPV 基因型、细胞学异常严重程度和 CIN2 的组织学特征。与 HPV16/18/33 相关的 HSIL/CIN2(+)可能需要早期治疗干预,而携带这些 HPV 基因型的 HSIL/CIN2(-)需要密切观察以检测 CIN3+的发生。对于没有 HPV DNA 的 CIN2,不建议进行治疗干预。